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Abstract 
Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-
methylcytosine (5mC) to promote the demethylation process. The reaction 
intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in 
embryonic stem cells and tissues, but strongly depleted in human cancers. Genetic 
mutations of TET2 gene were associated with leukaemia, whereas TET1 
downregulation has been shown to promote malignancy in breast cancer.  Here, we 
report that TET1 is downregulated in colon tumours from the initial stage. TET1 
silencing in primary epithelial colon cells increase their cellular proliferation while its   
re-expression in colon cancer cells inhibits their proliferation and the growth of 
tumour xenografts even at later stages. We found that TET1 binds and maintains 
hypomethylated the promoter of the DKK genes inhibitors of the WNT signalling. 
Downregulation of TET1 during colon cancer initiation leads to repression, by DNA 
methylation, the promoters of the inhibitors of the WNT pathway resulting in a 
constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation 
mediated by TET1 controlling the WNT signalling is a key player of tumour growth. 
These results provide new insights for understanding how tumours escape cellular 
controls.    
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Introduction 
DNA methylation plays essential role in the remodelling of the chromatin structure 
during development and tissue differentiation 1-5. Deficient DNA methylation 
establishment, due to mutation in DNA methyltransferases Dnmt3a or Dnmt3b, can 
lead to genetic diseases, such ICF syndrome, and differentiation-associated 
methylation patterns are found altered in the majority of human cancers 6-10. 
Irregular DNA methylation patterns are often associated with the tumour cells, where 
a general hypomethylation takes place together with hypermethylation of specific 
regions 7,9,11-13. Colon cancer is one of the most susceptible disease to the 
deregulation of DNA methylation and often the tumour initiation is due to genetic 
mutation accomplished by epigenetic inactivation of the WNT pathway inhibitors 
10,14-16. 
5-hydroxymethylcytosine (5hmC) is a recently discovered epigenetic modification 
catalysed by the Ten eleven translocation (TET) proteins that mediate the sequential 
oxidation of 5-methylcytosine (5mC) to 5hmC, leading to eventual DNA 
demethylation 17-21. 5hmC is lost in human cancers, but the functional significance of 
this event is not still understood 22-25. Several mechanisms can lead to loss of 5hmC 
in cancers, including mutations in IDH or TET2 genes 26-29. Reduced levels of 5hmC, 
associated with mutations or reduced expression of TET genes, have been 
implicated in myeloproliferative disorders 22-25,29-34. Downregulation of TET1 has 
been shown to promote cancer invasion and metastasis 35,36. Here we show that 
TET1 downregulation is not only linked to tumour progression and malignancy, but it 
is necessary for tumour initiation and growth. We reveal the molecular function of 
TET1 protein in cancer development and clarify the mechanism by which the WNT 
pathway inhibitors are epigenetically switched off during cellular transformation. This 
mechanism provides the explanation for specific promoter hypermethylations in 
cancer, which are TET-dependent, whereas a general hypomethylated state could 
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be caused by deregulation of the DNA methyltransferase machinery.  
 
 
 
Results 
 
TET1 downregulation is an early event in cell transformation 
We analysed the level TET1 and hydroxymethylation in colon tumours.  We found 
that TET1 and 5hmC are strongly reduced in primary colon cancers with respect to 
the surrounding healthy tissue (Figure 1a and b). Interestingly, in our samples TET1 
was downmodulated independently from the tumour stage and the histopathological 
grade (Supplementary Figure S1a). To understand how TET1 is regulated in 
tumours with respect in tumour initiation and progression, we analysed a 
metadataset from stages I to IV of colon, breast, lung, and rectum primary tumours. 
Analysis of the genes differentially expressed in this cohort of 887 adenocarcinomas 
revealed that TET1, but not TET2 or TET3, was strongly downregulated in tumours 
since stage I (Supplementary Figure S1b). These data demonstrate that TET1 
downregulation is an early event in tumourigenesis. Quantitative RT-PCR (RT-
qPCR) analysis showed TET1 expression in human colon tissues and in normal 
epithelial colon cells (CCD), which were positive for the 5hmC modification, while 
TET1 and 5hmC modification were almost undetectable in all the analysed colon 
cancer cell lines (Figure 1c and d). To understand TET1 functional role in colon cells 
we silenced TET1 in the normal CCD cells using two different short hairpin RNAs 
(shRNAs) (Figure S2a). TET1-knockdown CCD cells showed an increase in cell 
proliferation (Figure S2b) suggesting that TET1 plays a role in the control of cell 
growth. To perform a rescue experiment we silenced TET1 using the two shRNA 
together to increase the knockdown efficiency and re-expressed TET1 by using a 
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cDNA missing its 3’ UTR. TET1 re-expression in TET-silenced cell induced a full 
recovery of the level of 5hmC as well as a reduction of the cell proliferation 
rate (Figure 1e-g). 
 
TET1 blocks colon cancer cell growth in vitro and in vivo 
The above results show that TET1 is downregulated in colon cancers and that its 
downregulation in normal cells promotes cell proliferation. Next, we analysed the 
effects of TET1 re-expression on the growth of colon cancer cells. To this end we 
first generated Caco-2 and SW48 human colorectal carcinoma cell lines stably 
expressing TET1 under the control of a doxycycline-inducible (Dox) promoter 
(Figure 2a). TET1 expression did not alter TET2 or TET3 expression 
(Supplementary Figure S3a and b). Upon cell treatment with Dox, TET1 induced an 
increased level of 5hmC and strongly reduced the growth rate of both cell lines 
(Figure 2b and c). These effects were due to the enzymatic activity of TET1, which 
lengthens the G0/G1 phase of the cell cycle while the hydroxylase deficient mutant 
TET1-H1672Y/D1674A (TET1-mut) was not able to interfere with cell growth in vitro 
(Supplementary Figure S3 c-f). Since both Caco-2 and SW48 form spheres under 
serum-free conditions (Supplementary Figure S4a and b) we also tested the effect 
of TET1-dependent hydroxymethylation on tumour initiating cells. TET1 induction 
caused a significant reduction of sphere formation (Figure 2d). We analysed the 
surface markers CD166, CD44, and EpCAM that increase during sphere growth 37 
but we did not observe any changes of these markers in Caco-2 or SW48 cells after 
TET1 re-expression suggesting that TET1 decreases cell proliferation independently 
from the cell fraction source and that it does not favor the proliferation of any 
particular fraction (Figure S4c).  
To evaluate whether TET1 plays a role in tumour growth in vivo we injected the 
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Caco-2 and SW48 cell lines in nude mice. A group of animals were then treated with 
Dox to induce the expression of TET1 (Figure 3a). The size and weight of 
xenografts expressing TET1 were dramatically smaller than the control group in 
which TET1 was not induced (Figure 3b, c, and d, and Supplementary Figure S5a). 
TET1 expression blocked the growth of the tumours derived from both cell lines from 
the beginning (Figure 3b). Remarkably, growth arrest was obtained not only when 
TET1 was induced early after tumour cells inoculation but also when TET1 was 
induced when the tumours were already established several days later (Figure 3e 
and Supplementary Figure S5b). These results are consistent with the strong 
inhibition of cell growth observed in vitro.  
 
TET1 inhibits WNT signalling pathway 
To understand the molecular function of TET1 expression on colon cancer, we 
performed a genome-wide RNA-Seq analysis of the mRNA of Caco-2 cells treated 
for 96h with doxycycline. This analysis revealed that TET1 alters the expression of 
about 300 genes of which more than 60% were upregulated (Figure 4a). 
Interestingly, analysis of the genome-wide methylation pattern of wild type Caco2 
cells 38 showed that the genes upregulated by TET1 where those that exhibited a 
significant higher methylation level on their promoters (Figure 4b). Gene ontology 
analysis showed a significantly enrichment in the WNT/β-catenin signalling pathway 
(p-value < 0.001) of the TET1-deregulated genes and many of them are involved 
directly or indirectly to the canonical WNT pathway (Figure 4c and d). We measured 
the level of nuclear β-catenin (CTNNB1) and we observed its reduced nuclear 
localization after TET1 re-expression in both cancer cell lines (Figure 4e and f). We 
then analysed the effect of TET1 expression on the WNT/β-catenin signalling 
pathway by using the TCF/LEF-dependent luciferase reporter assay since these 
cancer cells show high activity of this pathway (Supplementary Figure S6a). TET1 
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induced a downregulation of WNT/β-catenin signalling in both cell lines (Figure 4g). 
Also in this case, the enzymatic activity of TET1 was required to downmodulate the 
WNT pathway activity (Supplementary Figure S6b). To demonstrate that the 
decreased proliferation rate was due to the TET1-dependent inactivation of the WNT 
pathway, we expressed a stable nuclear β-catenin in the Caco-2 and SW48 lines 
treated with Dox (Figure 4h). The expression of β-catenin in these cells rescued the 
luciferase activity and the cell growth (Figure 4i and Supplementary Figure S6c) 
demonstrating that the TET1-induced block of cell proliferation acts via WNT 
pathway inhibition. Interestingly, immunofluorescence analysis and Western blot of 
nuclear extracts of 24 days old xenografts showed sustained β-catenin nuclear 
localization in untreated but not in Dox treated mice (Figure S6d and e) indicating 
that also in vivo occurs a reduced WNT pathway activity in TET1 expressing 
tumours. 
 
TET1-dependent demethylation promotes transcriptional activation of the 
WNT pathway inhibitors 
RNA-Seq analysis showed proliferation-associated genes dowregulated in TET1 
expressing Caco-2 cells, such as MYC and Cyclin D2 (CCND2) that are 
downstream targets of the WNT pathway. Importantly, DKK and SFRP genes, that 
are upstream inhibitors of the WNT pathway, were found upregulated in TET1 
expressing cells (Figure 5a). RT-qPCR analysis at 96 hours after Dox treatment 
showed the upregulation of DKK3 and DKK4 and the downregulation of MYC and 
Cyclin D2 in both the cell lines (Figure 5b). Chromatin Immunoprecipitation (ChIP) 
analysis showed the binding of TET1 on the promoters of DKK genes (Figure 5c). 
Analysis of the level of 5hmC and 5mC revealed a significant increase of 5hmC on 
the DKK3 and DKK4 genes associated with a reduction of 5mC signal (Figure 5d 
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and e). Interestingly, DKK1 and DKK2 expression was not affected by TET1 (Figure 
5b).  DKK1 was not methylated suggesting that on this gene the transcriptional 
repression is not mediated by DNA methylation. DKK2 showed an elevated level of 
DNA methylation, which was not significantly reduced by TET1 expression at 96 
hours after Dox treatment (Figure 5e). To demonstrate that TET1 functions via 
repressing of the WNT inhibitors we performed a rescue experiment in which we 
silenced the DKK3 and DKK4 genes and re-expressed TET1 in Caco-2 and SW48 
cells (Figure 5f). We used two different shRNAs to perform the knockdown of each 
DKK gene. The knockdown of both DKK3 and DKK4 restored the cell growth 
inhibition by TET1 expression (Figure 5g). Interestingly, RT-qPCR analysis of Caco-
2 and SW48 tumour xenografts at later time points showed DKK3 and DKK4 
upregulation as well as MYC and Cyclin D2 downregulation (Figure S7). It is worth 
noting that the tumours expressed also DKK2 (Figure S7), which was not 
upregulated within 96 hours of TET1 expression (Figure 5b) suggesting a 
cumulative TET1-dependent demethylation on the DKK2 promoter in xenografts. 
Taken together the above data demonstrate that TET1 inhibits cancer cells growth 
by repressing the WNT pathway, via demethylation of the promoters of the WNT 
inhibitors DKK3 and DKK4.   
 
 
Discussion 
We here demonstrate that TET1 loss in colon cancer is an early event that favours 
cell proliferation. We propose a model by which TET1 downmodulation contributes 
to tumour initiation. Indeed, our data show that TET1 silencing in normal epithelial 
colon cells facilitates cell cycle progression and that its re-expression in transformed 
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colon cells blocks cell growth. Accordingly, meta-analysis on a cohort of 887 
adenocarcinomas showed that TET1 mRNA is downregulated from the first stage of 
tumours, especially in colon-rectal cancers. Thus the downmodulation of TET1 takes 
place already at their initial stage suggesting that, in order to grow, cancer cells 
must downregulate TET1 expression. 
Our work demonstrated that TET1 downmodulation is required for cancer cell 
growth as its re-expression in cancer cells inhibits their growth both in vitro and in 
vivo. We found that TET1 oncosuppressor function is mediated by its enzymatic 
activity, since the catalytically dead mutant was unable to block cancer cell growth.  
The significant increase of 5hmC in TET1 expressing cells suggests that this 
modification could play gene regulatory functions in addition of being an 
intermediate for C-demethylation 39,40 
It has been previously shown in breast tissue that TET1 is required to maintain the 
expression of the antimetastatic miR200 and TIMP genes by inhibiting the 
methylation on their promoters and its downregulation in breast cancer results in the 
lower expression of these genes 35,36. In contrast, in colon cancers, we could not find 
expression of miR200 or the downregulation of TIMP genes  (data not shown). 
Instead, we found that TET1 targeting the DKK and SFRP genes induced a 
reduction of the 5mC and an increase of the 5hmC marks on their promoter regions 
leading to the expression of these genes.  
Thus, in colon tumours the downregulation of the inhibitors of the WNT pathway, 
DKKs and SFRPs, due to TET1 downmodulation, results in the increased of tumour 
growth. This implies that in different tissues, due to the cell-specific epigenetic 
landscape, cells respond with different phenotypic outputs to TET1 downmodulation.  
WNT pathway inhibitors DKKs and SFRPs are epigenetically inactivated by DNA 
methylation in colorectal cancer cells and this event is able to sustain tumour 
development 14,15,41. Repression of these inhibitor genes allows a constitutive WNT 
signalling that sustains the proliferation of cancer cells. Our data demonstrate that 
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the gain of DNA methylation on these promoters is due to the reduced TET1-
dependent demethylation activity. 
In colon cancer cells, the loss of TET1 promotes DNA methylation of these 
promoters leading to a full repression of the genes, which is revertible by TET1 re-
expression.  
In summary, our data show that TET1 acts as an oncosuppressor because it plays a 
central role in the epigenetic control of colon cancer growth. TET1 reactivation, 
although challenging, can represent a novel therapeutic approach in cancer.  
  
 11 
Material and methods 
Cell culture, transfection and transduction  
Caco2 and SW48 cells were cultured in RPMI medium with 10% FCS. For 
Doxycycline-inducible stable clone generation Caco2 and SW48 cells were 
transduced with 10 µl of concentrated virus of pLVX-Tight-Puro-TET1 and pLVX-
Tet-On-Advanced Vectors and selected for 7 days in Puromycin 1 mg/ml and 
Hygromycin B 100 mg/ml. For induction of TET1, Doxycycline was used at 1 mg/ml. 
Transfections were performed using Lipofectamine 2000 Transfection Reagent 
(Invitrogen) according to the manufacturer’s protocol. CCD normal colon epithelial 
cells were acquired from ATCC (CCD 841 CoN (ATCC® CRL-1790™) and cultured 
as described by ATCC. For shRNA transduction, 10 µl of concentrated virus of 
PLKO vectors were incubated with cells for 16 hours. 
 
Animals 
C57BL/6 mice (8-10 weeks old) were obtained from our mouse facility. BALB/c-nude 
(6 weeks old) were obtained from Janvier-labs. Housing and all experimental animal 
procedures were approved by the Institutional Animal Care and Research Advisory 
Committee of the University of Turin. 
 
Constructs 
pAAV-EF1a-HA-hTet1CD-WPRE-PolyA and pAAV-EF1a-HA-hTet1CDmu-WPRE-
PolyA were purchased from Addgene (plasmid 39454 and 39455). pLVX-Tight-Puro 
Vector and pLVX-Tet-On-Advanced Vector were purchased from Clontech (plasmid 
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S4934 and S4932). Catalytic domain of TET1 was sub-cloned into pLVX-Tight-Puro-
Vector. TET1, DKK3 and DKK4 shRNAs were constructed using the TRC hairpin 
design tool (http://www.broadinstitute.org/rnai/public/seq/search) choosing the  
following   hairpin sequences:  
ACACAACTTGCTTCGATAATT (TET1, shRNA1) 
TTGTGCCTCTGGAGGTTATAA (TET1, shRNA2).  
GACACGAAGGTTGGAAATAAT (DKK3, shRNA1) 
GGCATGCACATCTGGAATTAA (DKK3, shRNA2).  
TCGGCAGCATGCTCGATTAAG (DKK4, shRNA1) 
GGAAGCCAAGTATTAAGAAAT (DKK4, shRNA2).  
Annealed oligonucleotides were cloned into pLKO.1 vector (Addgene: 10878) and 
each construct was verified by sequencing. Super8X-TOPFlash, negative control 
Super8X-FOPFlash and pCS2-CTNNB1-S33A-myc-tag were kindly provided by 
Professor Valeria Poli.   
 
Antibodies 
The antibodies were purchased from Millipore (anti-TET1), Abcam (anti-ssDNA), 
Cell Signalling (anti-CD44-8E2, anti-EpCAM), Sigma-Aldrich (anti-B-actin), 
Epitomics (anti-CD166), BD Transduction Laboratory (anti-CTNNB1), SantaCruz 
(anti-LaminA-sc20680), and Active Motif (anti-5mC, anti-5hmC). 
 
DNA Extraction and dot-blot analysis 
Genomic DNA was extracted from cells using DNeasy Blood and Tissue kit 
(Qiagen). For dot-blot analysis, extracted genomic DNA was sonicated for 15 cycles 
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to obtain 300 bp fragments, denatured with 0.4 M NaOH and incubated for 10 min a 
95°C prior to being spotted onto HybondTM-N+ (GE Healthcare). Membrane were 
saturated with milk 5% and incubated 16h with the specific antibodies. 
 
RNA extraction and RT-PCR analysis 
RNA extraction and RT-PCR were performed as in 42. Briefly, total RNA was 
extracted using TRIzol reagent (Invitrogen). Real-time PCR was performed using 
the SuperScript III Platinum One-Step Quantitative RT- PCR System (Invitrogen, 
cat.11732-020) following the manufacturer’s instructions. Primers sequences are 
provided in Supplementary Table S1. 
 
RNA sequencing 
For mRNA-Seq, libraries were generated from total RNA using TruSeq RNA Sample 
Preparation v2 in according to the manufacturer’s protocol. Samples were 
sequenced on Illumina HiScanSQ platform. Reads were mapped on hg19 using 
TopHat v2.0.6 43 and mRNA quantification was performed using Cuffdiff v2.0.2 44. 
Up- and down-regulated genes are provided in Supplementary Table S3. Raw data 
are deposited under the GEO accession GSE53172. 
 
ChIP and (h)MeDIP 
ChIP were performed as in 45. For MeDIP and hMeDIP, 2 µg of sonicated DNA was 
denatured at 95°C for 10 minutes, immediately cooled on ice for 10 minutes and 
diluted in 400 µl of IP buffer (10 mM Na-Phosphate pH 7.0 140 mM NaCl 0.05 % 
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Triton X-100) with 10 µl of anti-5mC or anti-5hmC. After incubation of 2 hours with at 
4°C with overhead shaking, 30 µl of saturated Dynabeads anti-mouse IgG were 
added and incubate for other 2 hours. After five washes with IP buffer, DNA was 
eluted with Proteinase K for 2 hours and purified using the QIAQuick PCR 
Purification Kit (QIAGEN) according to the manufacturer’s instructions. DNA was 
DNA was analyzed by quantitative real-time PCR by using a SYBR GreenER kit 
(Invitrogen). Primers sequences are provided in Supplementary Table S2. 
 
Protein extraction and Western blotting 
Extracts were performed as previously described 46. Briefly, cells were resuspended 
in F-buffer (10mM TRIS-HCl pH 7.0, 50mM NaCl, 30mM Na-pyrophosphate, 50mM 
NaF, anti-proteases) and sonicated for 3 pulses to obtain total cell extracts. Nuclear 
protein extraction was performed as in 3. Extracts were quantified using 
bicinchoninic acid (BCA) assay (BCA protein assay kit; catalog no. 23225; Pierce) 
and were run in SDS-polyacrylamide gels at different percentages, transferred to 
nitrocellulose membranes and incubated 16 hours with specific primary antibodies.  
 
Luciferase assay 
Cells were transfected with the indicated Firefly luciferase reporter constructs with 
1/10 of Renilla Luciferase reporter construct. After 24 h cells were analyzed for 
luciferase and Renilla activity using a Dual-Glo luciferase assay (Promega). 
Promoter activity values were normalized using Renilla activity. 
 
Immunofluorescence 
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For immunostaining tumours were dissected and fixed in 2% PAF overnight at 4°C, 
dehydrated and embedded in paraffin. Thick sections (5 µm thickness) were then 
incubated with anti-CTNNB1 antibody.  
 
Cell growth and cell cycle analysis 
For cell growth assay, 5x104 cells were plated in 35mm wells and counted at the 
indicated time point using Scepter™ Automated Cell Counter (Millipore). For FACS 
cell cycle analysis, the cells were stained with propidium iodide (PI) solution 
(0.1%Triton, 200 mg/ml RNase, 20 mg/ml PI in PBS) for 30 min at room 
temperature. Acquisition was performed using Becton Dickinson FACS Canto and 
analysis was done with FACS FlowJo Software. 
 
FACS analysis 
FACS analysis was performed as previously described (Neri et al., 2012) Briefly, 
cells were first incubated with primary antibodies for 30 minutes in PBS-1% bovine 
serum albumin (BSA) and after 3 washes were stained with conjugated secondary 
antibodies. 
 
Colonsphere assay 
Colonsphere assay was performed as in 37 with the following modifications: cells 
were plated as single cell in 96 well round bottom in DMEM/F12 medium 
supplemented with BSA 0.4%, Heparin 4mg/ml, Insulin 20mg/ml, B27, N2, bFGF 
10ng/ml, EGF 20ng/ml and cultured for 10 days before analysis. 
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Mouse and tumours injection 
Caco2 and SW48 human colon tumour cell lines were harvested and single-cell 
suspensions of 1x106 in 100 ul of PBS were injected subcutaneously into the right 
flank of mice. Tumour volumes were measured every two days with a caliber using 
the formula: V = π x [d2 x D] / 6, where d is the minor tumour axis and D is the 
major tumour axis. The mice were sacrificed at defined time intervals after cell 
inoculation or when tumours reached a maximum size of 2 cm3.  
 
Bioinformatics analysis 
Gene expression analysis of TET1, TET2 and TET3 was performed using The 
Cancer Genome Atlas TCGA database (http://cancergenome.nih.gov/) subdividing 
the cancers for their reported tumour stage where it was available, otherwise the 
data were not used. Gene ontology was performed using DAVID software 47,48 
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Figure legends 
Figure 1.  
Correlation between TET1/5hmC and (cancer) cell proliferation. (a) qRT-PCR 
of TET1 mRNA in colon tumours samples and their relative healthy tissues. 
Error bars represent the standard deviation of 3 technical replicates. (b) Dot-
blot analysis of 5hmC and 5mC in colon tumours samples and their relative 
healthy tissues. ssDNA was used as loading control. (c) qRT-PCR of TET1 
mRNA in the indicated cancer lines or primary cells. (d) Dot-blot analysis of 
5hmC and 5mC in the indicated cancer lines or primary cells. ssDNA was 
used as loading control. (e) qRT-PCR of TET1 mRNA in CCD normal human 
colon cells treated with a control shRNA, with two different shRNA against 
TET1 or with two different shRNA against TET1 plus TET1 cDNA. (f) Dot-blot 
analysis of 5hmC and 5mC in CCD cells treated as in (e). ssDNA was used 
as loading control. (g) Cell growth assay in in CCD cells treated as in (e). 
Error bars represent the standard deviation of 3 independent experiments. 
 
 
Figure 2. 
TET1 regulates cancer cell proliferation. (a) Western Blot (WB) analysis of 
TET1 in control or Doxycycline (Dox) treated Caco2 or SW48 colon cancer 
cell lines expressing inducible TET1. ACTB was used as loading control. (b-
c) Dot-blot analysis of 5hmC and cell growth assay of wt or TET1 inducible 
expressing (± Dox) Caco2 and SW48 cell lines. (d) Quantification of 
colonspheres obtained in colonspheres assay using the cell lines treated as 
in (c). Error bars represent the standard deviation of 3 independent 
experiments. (* pvalue < 0.01) 
 
 21 
 
Figure 3. 
TET1 inhibits cancer growth. (a) qRT-PCR of TET1 mRNA in the indicated 
cell line xenografts after 3 weeks. (b) Mouse tumour growth of TET1 
inducible expressing (± Dox) Caco2 and SW48 cell line respectively. (c) 
Macroscopic view showing tumours upon resection from BALB/c-nude mice 
respectively of  Caco2 and SW48 cell line implanted subcutaneously. (d) 
Tumours weight upon resection. (e) Reduced tumour growth of Caco2 and 
SW48 cell line by TET1 expression upon post-implantation Doxycycline (Dox) 
treatment from the indicated day. Error bars in the Fig. represent the 
standard deviation of at least 3 independent experiments. 
  
 
Figure 4. 
TET1 negatively regulates Wnt pathway in cancer cells. (a) Up- and down- 
regulated genes obtained from RNA-Seq analysis in Caco2 cell line 
expressing TET1 for 96h. (b) Promoter methylation percentage of the up- 
and down- regulated gene in Caco2 after 96h. Promoter methylation was 
calculated using RRBS data from Encode (GSM980582) as the percentage 
of methylated CpGs in the region between -1000/+500 from TSS. (c) Gene 
Ontology (GO) analysis of deregulated genes in Caco2 cell line expressing 
TET1 after 96h. (d) Schematic representation of the canonical WNT pathway 
with in red the up-regulated genes and in blue the down-regulated genes by 
TET1 expression in Caco2 cell line. (e) WB analysis of CTNNB1 in nuclear 
(Nuc) or cytoplasmatic (Cyt) extracts of Caco2 or SW48 cells treated with 
Dox at the indicated times. LAMIN A and ACTIN was used as loading control. 
(f) Nuclear localization loss of CTNNB1 in Doxycycline treated or untreated 
CACO-2 and SW48 cells for 48hours. DAPI is used for nuclei staining.  (g) 
Caco2 and SW48 cells were transfected with a WNT-reporter (firefly TOP 
vector) and a Renilla luciferase (normalizing transfection control) constructs. 
The reporter activity was measured 24h after transfection in cells treated or 
not with Dox for 24h or 96h. (h) WB analysis of CTNNB1 in total extracts of 
Caco2 or SW48 cells treated with Dox and transfected with Mock or CTNNB1 
(active form S33A). ACTB was used as loading control. i) Cell growth assay 
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in Mock or CTNNB1 transfected Caco2 and SW48 cells treated with Dox for 
TET1 induction. Error bars in the Figure represent the standard deviation of 3 
independent experiments.  
 
Figure 5. 
TET1 derepresses WNT inhibitors. (a) Heatmap of the most regulated genes 
of the WNT pathway. (b) qRT-PCR of DKKs, MYC and CCND2 mRNA levels 
in Caco2 and SW48 cell lines ± Dox treatment. (c) ChIP analysis of the DKK 
gene promoters in Caco-2 and SW48 cells ± Dox treatment. (d-e) (h)MeDIP 
analysis of DKK gene promoters in Caco-2 and SW48 cells ± Dox treatment. 
(f) RT-qPCR of DKK3 and DKK4 in Caco2 and SW48 treated with Dox and 
transfected with control or DKK3 and DKK4 shRNAs. (g) Cell growth assay in 
Caco2 and SW48 cells treated as in (f). Error bars represent the standard 
deviation of 3 independent experiments. (* pvalue < 0.01, ** pvalue < 0.05). 
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